Rathbones Group’s Oramed Pharmaceuticals ORMP Stock Holding History

Rathbones Group’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Hold	233,018	–	–	﹤0.01%	355
2026 Q1	$792K	Hold	233,018	–	–	﹤0.01%	400
2025 Q4	$664K	Hold	233,018	–	–	﹤0.01%	420
2025 Q3	$615K	Hold	233,018	–	–	﹤0.01%	419
2025 Q2	$524K	Sell	233,018 -3,785	-2%	-$8.35K	﹤0.01%	425
2025 Q1	$507K	Sell	236,803 -53,000	-18%	-$122K	﹤0.01%	410
2024 Q4	$701K	Hold	289,803	–	–	﹤0.01%	370
2024 Q3	$707K	Hold	289,803	–	–	﹤0.01%	367
2024 Q2	$745K	Hold	289,803	–	–	﹤0.01%	358
2024 Q1	$846K	Hold	289,803	–	–	﹤0.01%	345
2023 Q4	$669K	Hold	289,803	–	–	﹤0.01%	355
2023 Q3	$756K	Buy	+289,803	New	+$913K	0.01%	343

Other funds holding ORMP

STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return

SCM

Sage Capital Management Stockton, New Jersey $256M AUM 29.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

GJIA

Glass Jacobson Investment Advisors Owings Mills, Maryland $321M AUM 20.69% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PFO

Pioneer Family Office North Miami Beach, Florida $194M AUM

SCM

Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Rathbones Group's ORMP Position: Q2 2026 in Review

Rathbones Group held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2026 at 233,018 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #355.

Rathbones Group first reported a position in ORMP in Q3 2023 and has held it in 12 quarters since. 14 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

Rathbones Group held 233,018 shares of Oramed Pharmaceuticals worth $1.12M as of Q2 2026.
Rathbones Group left its Oramed Pharmaceuticals share count unchanged in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #355 holding.
Rathbones Group first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
14 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.